Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olomorasib in hepatic impairment
NCT06719128Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration at 96 hours and Area Under the Concentration Versus Time Curve from Time Zero to Infinity at 96 hours. Started Dec 2024; status: completed.
02
Drugs
olomorasib
Beyond the preview
Go deeper on NCT06719128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719128.